Clay Cramer, MS, DABT
Clay has 30+ years of drug research and development experience leading new chemical entities through nonclinical development and approval in US and EU markets. Mr. Cramer started his career at The Upjohn Company in investigative toxicology in support of nonclinical drug discovery and development across broad therapeutic areas. In 1998, Clay joined the Esperion Therapeutics Company in support of biologic product development and small molecule discovery. Efforts which led to the acquisition of Esperion for $1.2B by Pfizer in 2004. In 2004, Clay was lead scientist at Pfizer responsible for identifying macromolecules with HDL-like properties. In 2008, Clay joined the second iteration of Esperion as the Director of Nonclinical Development to lead the successful nonclinical development of bempedoic acid. In 2019, Nexletol and Nexlezet products were approved in the US and EU. In 2019, Clay founded Nonclinical Development Solutions, LLC to provide toxicology support and pharmaceutical development services.